TSC2 and acute myeloid leukemia: Studies have shown that TSC2-deficient cells have a reduced sensitivity to the growth inhibitory effects of IFN-β and that re-expression of TSC2 restores the anti-proliferative properties of this cytokine.31 Our results may explain this phenomenon, as we show here that the IFN type 1 response is heightened in TSC2-deficient AML cells independently of IFN-β expression.